美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Decoy Therapeutics Inc

1.25

+0.435053.37%

盘前：1.06-0.1900-15.20%04:46 EST

成交量：1.09亿

成交额：1.43亿

市值：798.03万

市盈率：-0.03

高：1.41

开：1.35

低：1.07

收：0.8150

52周最高：52.95

52周最低：0.5148

股本：638.42万

流通股本：634.11万

量比：72.71

换手率：1715.96%

股息：- -

股息率：- -

每股收益(TTM):-39.1909

每股收益(LYR):-86.9214

净资产收益率：-139.55%

总资产收益率：-69.91%

市净率：1.88

市盈率(LYR):-0.01

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Decoy Therapeutics Inc

交易所：

NASDAQ

成立时间：

- -

员工人数：

2

公司地址：

One Broadway,14th Floor,Cambridge,Massachusetts,United States

官网：

http://www.salariuspharma.com

邮编：

02142

电话：

- -

传真：

- -

简介：

Decoy Therapeutics Inc.是一家于2014年2月26日在特拉华州注册成立的生物技术公司，并且其业务主要发生在马萨诸塞州的波士顿。该公司是一家临床阶段的生物制药公司，专注于为癌症患者开发创新治疗选择。其产品组合包括 seclidemstat，这一主要候选药物目前正在MD安德森癌症中心进行1/2 阶段临床研究，旨在针对骨髓增生异常综合症 (MDS) 和慢性髓单核白血病 (CMML) 等血液系统癌症，特别是为治疗选择有限的患者开发。此外，公司还在推进SP-3164，这是一种口服小分子蛋白降解剂，目前处于新药研究阶段 (IND)。

董事

名称

职位

Frederick E. Pierce

Director and Chief Executive Officer

William K. McVicar

Chair

Arnold C. Hanish

Director

David J. Arthur

Director

Jonathan Lieber

Director

Paul Lammers

Director

Tess Burleson

Director

股东

名称

职位

Frederick E. Pierce

Director and Chief Executive Officer

Mark J. Rosenblum

Executive Vice President of Finance and Chief Financial Officer

Barbara Hibner

Chief Scientific Officer

Peter Marschel

Chief Business Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/DCOY/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DCOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":1.25,"timestamp":1768338000000,"preClose":0.815,"halted":0,"volume":108810866,"hourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.25,"latestTime":"04:46 EST","volume":8227,"amount":8589.7917779,"timestamp":1768383997633},"delay":0,"floatShares":6341106,"shares":6384200,"eps":-39.1909,"marketStatus":"盘前交易","change":0.435,"latestTime":"01-14 04:46:58 EST","open":1.35,"high":1.41,"low":1.07,"amount":142501332.4554706,"amplitude":0.417178,"askPrice":1.09,"askSize":100,"bidPrice":1.06,"bidSize":1421,"shortable":3,"etf":0,"ttmEps":-39.1909,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768401000000},"marketStatusCode":1,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.25,"latestTime":"04:46 EST","volume":8227,"amount":8589.7917779,"timestamp":1768383997633},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.25,"latestTime":"19:59 EST","volume":1719614,"amount":1907282.5938,"timestamp":1768352390180},"volumeRatio":72.70843687745302},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","floatShares":6341106,"roa":"-69.91%","roe":"-139.55%","lyrEps":-86.921415,"volumeRatio":72.70843687745302,"shares":6384200,"dividePrice":0,"high":1.41,"amplitude":0.417178,"preClose":0.815,"low":1.07,"week52Low":0.5148,"pbRate":"1.88","week52High":52.95,"institutionHeld":0,"latestPrice":1.25,"committee":0.868508,"eps":-39.1909,"divideRate":0,"volume":108810866,"delay":0,"ttmEps":-39.1909,"open":1.35,"prevYearClose":0.6488,"prevWeekClose":0.8198,"prevMonthClose":0.6488,"prevQuarterClose":0.6488,"fiveDayClose":0.65,"twentyDayClose":0.78,"sixtyDayClose":4.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DCOY\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DCOY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DCOY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DCOY","date":"2026-01-12","current":-0.031895,"percent":0.5,"low":-1.071522,"twenty":-1.061215,"median":-1.045754,"eighty":-1.007639,"high":-0.982229,"avg":-1.033168,"sd":0.037524,"marketCap":5233748},"quantilePoints":[{"date":"2026-01-09","current":-0.982229,"twenty":-1.053663,"median":-1.026876,"eighty":-1.000088,"marketCap":4915816},{"date":"2026-01-12","current":-1.045754,"twenty":-1.061215,"median":-1.045754,"eighty":-1.007639,"marketCap":5233748}],"updateTime":1768377258142},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":330031056,"employeeNum":2,"address":"One Broadway,14th Floor,Cambridge,Massachusetts,United States","zipCode":"02142"},"stockCompanyDetail":{"websiteUrl":"http://www.salariuspharma.com","stockEarnings":[{"period":"1week","weight":0.9231},{"period":"1month","weight":0.6026},{"period":"3month","weight":-0.7283},{"period":"6month","weight":-0.8641},{"period":"1year","weight":-0.9773},{"period":"ytd","weight":0.9266}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Decoy Therapeutics Inc.是一家于2014年2月26日在特拉华州注册成立的生物技术公司，并且其业务主要发生在马萨诸塞州的波士顿。该公司是一家临床阶段的生物制药公司，专注于为癌症患者开发创新治疗选择。其产品组合包括 seclidemstat，这一主要候选药物目前正在MD安德森癌症中心进行1/2 阶段临床研究，旨在针对骨髓增生异常综合症 (MDS) 和慢性髓单核白血病 (CMML) 等血液系统癌症，特别是为治疗选择有限的患者开发。此外，公司还在推进SP-3164，这是一种口服小分子蛋白降解剂，目前处于新药研究阶段 (IND)。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.099389},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.047904},{"month":3,"riseRate":0.454545,"avgChangeRate":0.000826},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.073659},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.005048},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.047064},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.136217},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.111993},{"month":9,"riseRate":0.090909,"avgChangeRate":-0.12638},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.128321},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062226},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.07199}],"exchange":"NASDAQ","name":"Decoy Therapeutics Inc","nameEN":"Decoy Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":{"directors":[{"name":"Frederick E. Pierce","position":"Director and Chief Executive Officer"},{"name":"William K. McVicar","position":"Chair"},{"name":"Arnold C. Hanish","position":"Director"},{"name":"David J. Arthur","position":"Director"},{"name":"Jonathan Lieber","position":"Director"},{"name":"Paul Lammers","position":"Director"},{"name":"Tess Burleson","position":"Director"}],"executives":[{"name":"Frederick E. Pierce","position":"Director and Chief Executive Officer"},{"name":"Mark J. Rosenblum","position":"Executive Vice President of Finance and Chief Financial Officer"},{"name":"Barbara Hibner","position":"Chief Scientific Officer"},{"name":"Peter Marschel","position":"Chief Business Officer"}]}}}